Pharmaceutical

STAT+: Most large U.S. funders of clinical research hav...

A new analysis finds that only 37% of the 14 largest public and philanthropic or...

STAT+: Why do some blood stem cells go rogue? Study off...

A common blood stem cell complication known as CHIP can turn cancerous. A new st...

STAT+: Pharmalittle: Merck to acquire Prometheus Biosci...

Merck plans to acquire Prometheus Biosciences, adding a pipeline of experimental...

Q&A: What does it mean when a clinical trial is delayed...

What does it mean when a clinical trial is delayed? More than one may think, sai...

Free Uber rides helped patients keep their prenatal app...

Uber says patients who participated in a pilot were slightly more likely to get ...

Opinion: OTC naloxone is a baby step toward making the ...

The new over-the-counter status for naloxone is a no-brainer. But as people who ...

Interview: Dr Alan S Louie – US Food and Drug Administr...

The US Food and Drug Administration has come under criticism recently for delays...

Beating the Big C

The global market for cancer drugs is growing rapidly, but are we any closer to ...

Reality Bites: Disappointment in the R&D Sector

The pharmaceuticals industry is investing twice as much in R&D as it was a decad...

Amendments Set to Clear Ambiguity

The US government is imposing transparency rules on the relationship between phy...

The Witty Answer to GSK’s Future

Has Andrew Witty got what it takes to keep GlaxoSmithKline at the top? Nicola Bo...

Tracking the Drug Trail

Counterfeiting and fraud are significantly large risk factors when it comes to t...

test

Japan’s M&A Boom

Japan's acquisitions market has seen surprising growth in recent times, as gener...

The Future for Biotesting

The pharmaceutical industry's annual CPhI exhibition is approaching, showcasing ...

The Biotech Effect

Catherine Lafferty looks at the rising influence of biotech on the renewed focus...